Objective:To study the value of serum tumor markers CA125, CA153, CEA, -hCG, CA199, CYFRA21-1, beta and TPS cytokines IL-6, TNF- alpha, IL-8 and GDF-3 levels in the diagnosis of breast cancer, and provide reference fo...Objective:To study the value of serum tumor markers CA125, CA153, CEA, -hCG, CA199, CYFRA21-1, beta and TPS cytokines IL-6, TNF- alpha, IL-8 and GDF-3 levels in the diagnosis of breast cancer, and provide reference for clinical diagnosis and treatment. Methods:A total of 293 cases of breast cancer patients admitted to our hospital from November 2015 to November 2017 were selected as the observation group. Besides, 125 patients with benign breast disease and 125 healthy people who came to our hospital for physical examination were also selected as benign breast disease group and control group, respectively. Serum tumor markers and cytokine changes were detected by using multiple tumor markers protein chip detection system and enzyme-linked immunosorbent assay (ELISA) among three groups.Results: Serum tumor markers and cytokine levels of observation group were higher than those in control group and benign breast disease group, the differences were statistically significant;through comparing different groups at different breast disease stages, serum tumor markers increase with the elevated stage, the highest in stage IV breast cancer. The difference was statistically significant;When benign breast disease group was compared with the control group, there was no significant difference in each index.Conclusion: The serum tumor markers CA125, CA153, CEA, -hCG, CA199, CYFRA21-1, beta and TPS cytokines IL-6, TNF- alpha, IL-8, GDF-3 show higher expression level in breast cancer and increase with the elevated stage. Therefore, it is worthy of attention.展开更多
基金Hubei Provincial Natural Science Foundation Project No:2012FFA071.
文摘Objective:To study the value of serum tumor markers CA125, CA153, CEA, -hCG, CA199, CYFRA21-1, beta and TPS cytokines IL-6, TNF- alpha, IL-8 and GDF-3 levels in the diagnosis of breast cancer, and provide reference for clinical diagnosis and treatment. Methods:A total of 293 cases of breast cancer patients admitted to our hospital from November 2015 to November 2017 were selected as the observation group. Besides, 125 patients with benign breast disease and 125 healthy people who came to our hospital for physical examination were also selected as benign breast disease group and control group, respectively. Serum tumor markers and cytokine changes were detected by using multiple tumor markers protein chip detection system and enzyme-linked immunosorbent assay (ELISA) among three groups.Results: Serum tumor markers and cytokine levels of observation group were higher than those in control group and benign breast disease group, the differences were statistically significant;through comparing different groups at different breast disease stages, serum tumor markers increase with the elevated stage, the highest in stage IV breast cancer. The difference was statistically significant;When benign breast disease group was compared with the control group, there was no significant difference in each index.Conclusion: The serum tumor markers CA125, CA153, CEA, -hCG, CA199, CYFRA21-1, beta and TPS cytokines IL-6, TNF- alpha, IL-8, GDF-3 show higher expression level in breast cancer and increase with the elevated stage. Therefore, it is worthy of attention.